LYNX-1: A Phase 3 Study of 0.75% Phentolamine Ophthalmic Solution in Subjects with Dim Light Vision Disturbances.

چکیده

To evaluate the efficacy and safety of 0.75% phentolamine ophthalmic solution (POS) for the treatment of dim light disturbances (DLD) in subjects with reduced mesopic low-contrast vision, including post-keratorefractive subjects. Phase 3, multicenter, double-masked, randomized, placebo-controlled…

متن کامل چکیده در سایت ناشر در دسترس است.

موضوعات مرتبط

• تنبلی چشم
• کم بینایی و توانبخشی